Shionogi signed an agreement to supply drugs to treat COVID-19 with the Japanese Government
Shionogi’s COVID-19 treatment pill named S-217622. (Photo: Reuters)
The Japanese government is considering buying 1 million courses medicine to treat COVID-19 of the company Shionogi pending regulatory approval of the drug, Shionogi added in a statement.
Shionogi’s shares jumped 3.9% after the news, compared with a 0.3% drop in the Tokyo benchmark index.
Shionogi can produce 10 million courses of COVID-19 pills per year. (Photo: Nikkei Asia)
In February 2022, Shionogi Company submitted an application for approval of its COVID-19 pill, a protease inhibitor (antiretroviral drug class) called S-217622. If approved, it will become the third antiviral drug approved to treat COVID-19 patients in Japan, after drugs developed by two pharmaceutical companies Pfizer and Merck.
Shionogi Company hopes to supply its COVID-19 treatment pills globally. Last week, a representative of Shionogi said that the company will launch phase 3 drug trials worldwide with the support of the US Government. Shionogi CEO Isao Teshirogi said that Shionogi’s COVID-19 pill production capacity can reach 10 million courses per year.
* Invite readers to watch programs broadcast by Vietnam Television on TV Online and VTVGo!
at Blogtuan.info – Source: vtv.vn – Read the original article here
